| Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases LP Jordheim, D Durantel, F Zoulim, C Dumontet Nature reviews Drug discovery 12 (6), 447-464, 2013 | 1318 | 2013 |
| Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA J Lucifora, Y Xia, F Reisinger, K Zhang, D Stadler, X Cheng, MF Sprinzl, ... Science 343 (6176), 1221-1228, 2014 | 1040 | 2014 |
| Hepatitis B virus X protein is essential to initiate and maintain virus replication after infection J Lucifora, S Arzberger, D Durantel, L Belloni, M Strubin, M Levrero, ... Journal of hepatology 55 (5), 996-1003, 2011 | 530 | 2011 |
| COVID-19: Discovery, diagnostics and drug development T Asselah, D Durantel, E Pasmant, G Lau, RF Schinazi Journal of hepatology 74 (1), 168-184, 2021 | 497 | 2021 |
| Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient JP Villeneuve, D Durantel, S Durantel, C Westland, S Xiong, CL Brosgart, ... Journal of hepatology 39 (6), 1085-1089, 2003 | 406 | 2003 |
| Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir MN Brunelle, AC Jacquard, C Pichoud, D Durantel, S Carrouée‐Durantel, ... Hepatology 41 (6), 1391-1398, 2005 | 370 | 2005 |
| Towards an HBV cure: state-of-the-art and unresolved questions—report of the ANRS workshop on HBV cure MB Zeisel, J Lucifora, WS Mason, C Sureau, J Beck, M Levrero, M Kann, ... Gut 64 (8), 1314-1326, 2015 | 312 | 2015 |
| New antiviral targets for innovative treatment concepts for hepatitis B virus and hepatitis delta virus D Durantel, F Zoulim Journal of hepatology 64 (1), S117-S131, 2016 | 233 | 2016 |
| Study of the mechanism of antiviral action of iminosugar derivatives against bovine viral diarrhea virus D Durantel, N Branza-Nichita, S Carrouée-Durantel, TD Butters, RA Dwek, ... Journal of virology 75 (19), 8987-8998, 2001 | 200 | 2001 |
| A targeted functional RNA interference screen uncovers glypican 5 as an entry factor for hepatitis B and D viruses ER Verrier, CC Colpitts, C Bach, L Heydmann, A Weiss, M Renaud, ... Hepatology 63 (1), 35-48, 2016 | 197 | 2016 |
| Persistence of the hepatitis B virus covalently closed circular DNA in HepaRG human hepatocyte-like cells O Hantz, R Parent, D Durantel, P Gripon, C Guguen-Guillouzo, F Zoulim Journal of General Virology 90 (1), 127-135, 2009 | 190 | 2009 |
| Antiviral therapies and prospects for a cure of chronic hepatitis B F Zoulim, D Durantel Cold Spring Harbor perspectives in medicine 5 (4), a021501, 2015 | 187 | 2015 |
| Control of hepatitis B virus replication by innate response of HepaRG cells J Lucifora, D Durantel, B Testoni, O Hantz, M Levrero, F Zoulim Hepatology 51 (1), 63-72, 2010 | 180 | 2010 |
| The HepaRG cell line: biological properties and relevance as a tool for cell biology, drug metabolism, and virology studies MJ Marion, O Hantz, D Durantel Hepatocytes: methods and protocols, 261-272, 2010 | 165 | 2010 |
| Hepatitis B virus requires intact caveolin-1 function for productive infection in HepaRG cells A Macovei, C Radulescu, C Lazar, S Petrescu, D Durantel, RA Dwek, ... Journal of virology 84 (1), 243-253, 2010 | 162 | 2010 |
| Receptor complementation and mutagenesis reveal SR-BI as an essential HCV entry factor and functionally imply its intra-and extra-cellular domains M Dreux, VL Dao Thi, J Fresquet, M Guérin, Z Julia, G Verney, D Durantel, ... PLoS pathogens 5 (2), e1000310, 2009 | 159 | 2009 |
| Celgosivir, an αglucosidase I inhibitor for the potential treatment of hepatitis C virus infection D Durantel Curr. Opin. Investig. Drugs 10 (8), 860-870, 2009 | 158 | 2009 |
| Early inhibition of hepatocyte innate responses by hepatitis B virus S Luangsay, M Gruffaz, N Isorce, B Testoni, M Michelet, S Faure-Dupuy, ... Journal of hepatology 63 (6), 1314-1322, 2015 | 155 | 2015 |
| Intrahepatic innate immune response pathways are downregulated in untreated chronic hepatitis B F Lebossé, B Testoni, J Fresquet, F Facchetti, E Galmozzi, M Fournier, ... Journal of hepatology 66 (5), 897-909, 2017 | 153 | 2017 |
| A new strategy for studying In Vitro the drug susceptibility of clinical isolates of human hepatitis B virus D Durantel, S Carrouée‐Durantel, B Werle‐Lapostolle, MN Brunelle, ... Hepatology 40 (4), 855-864, 2004 | 148 | 2004 |
